Weight-Loss Jabs 2026: Cost, Comparison and the Honest Picture on Wegovy, Mounjaro and Ozempic

Out of pocket in 2026 you pay roughly 104 to 482 euros a month depending on the drug and dose, and statutory health insurance (GKV) covers none of it when the goal is weight loss. That is the most important and most misunderstood point. All prices here are market estimates, as of 2026, depending on pharmacy and dose. On a private prescription each pharmacy sets its own price freely, there are no fixed reference amounts like there are for insurance-covered drugs. ^{[1, 2]}

Wegovy (semaglutide) runs about 172 to 277 euros a month. The low starting doses (0.25 / 0.5 / 1.0 mg) cost around 172 euros, the 1.7 mg dose around 236 euros and the maintenance dose 2.4 mg around 277 euros. ^{[1, 2]}

Mounjaro (tirzepatide) costs about 206 to 482 euros a month depending on dose and pack size. ^[1]

Ozempic (semaglutide) is the cheapest listed at around 104 to 200 euros a month. But careful: Ozempic is approved only for type 2 diabetes, using it to lose weight is off-label (outside the approval). More on that below, because cheap does not mean harmless here.

Why doesn't insurance pay? In Germany, medicines for weight loss have been excluded from coverage by law since 2004, as so-called lifestyle drugs under Section 34 (1) sentences 7 and 8 of SGB V (the German Social Code, Book Five). ^{[3, 4]} The Federal Joint Committee (G-BA, the top self-governance body in the German health system) formally enacted this exclusion for Wegovy on 21.03.2024 and added it to Annex II of the medicines directive. The decision took effect on 15.06.2024. ^[4]

A clear note is worth making here, because the opposite is circulating online: some sources claim insurance will reimburse the weight-loss jab from 15.06.2026. That is not true. The 15.06.2024 was the day the coverage exclusion became binding, that is the opposite of a reimbursement start. There is no date from which the GKV pays for the weight-loss jab for weight regulation.

And this holds even in the extreme case. Even with a very high BMI (over 40) plus comorbidities there is no entitlement to coverage, the G-BA has no discretion here. Social courts have confirmed this: the SG Darmstadt (S 13 KR 375/24, 2025) dismissed a claim for Mounjaro coverage from a patient with obesity, high blood pressure and sleep apnea, as did the SG Mainz (S 7 KR 76/24, 2025). ^{[5, 6]}

There is one exception: the diabetes indication. Ozempic and Rybelsus (semaglutide for type 2 diabetes) remain reimbursable for diabetics, because the lifestyle exclusion applies only when the approved indication is weight regulation. ^{[4, 5]}

On supply: in 2026 availability is markedly easier than in previous years, most doses are in stock. Regional or seasonal shortages, mainly of Wegovy, can still happen, that is a snapshot and may change. ^[7]

One budgeting catch that the marketing likes to skip: the monthly price is not the end of it. Because stopping typically triggers weight regain (more on that below), the weight-loss jab is in practice a long-term therapy. So if you want an honest calculation, reckon with monthly price times 12 times potentially many years. ^[9]

Drug	Active ingredient	Approval DE/EU	Out of pocket per month 2026	GKV for obesity?
Wegovy	Semaglutide	Obesity (weight management)	approx. 172 to 277 euros [1, 2]	No, Section 34 SGB V, G-BA Annex II [3, 4]
Mounjaro	Tirzepatide	Obesity and type 2 diabetes (EU)	approx. 206 to 482 euros [1]	No for obesity; diabetes prescription only [4, 5, 6]
Ozempic	Semaglutide	Type 2 diabetes only	approx. 104 to 200 euros [1]	Only as diabetes therapy; weight loss is off-label [1, 4]

In short: the three brand names hide only two active ingredients, and one works on average more strongly than the other. Ozempic and Wegovy both contain semaglutide, Mounjaro contains tirzepatide. The difference lies in the mechanism, the approval and the dosing.

Semaglutide (in Ozempic and Wegovy) is a pure GLP-1 receptor agonist. GLP-1 is a natural gut hormone released after eating. The drug mimics it: it slows gastric emptying, boosts the feeling of fullness, dampens appetite and promotes glucose-dependent insulin release. ^[8]

Tirzepatide (in Mounjaro) is a dual agonist, it acts on both the GIP and the GLP-1 receptor at the same time. GIP is a second gut hormone that also influences metabolism. This double action explains why tirzepatide tends to act more strongly on weight and blood sugar. ^{[8, 9]}

The brand names sort out like this: semaglutide is called Ozempic (diabetes) and Wegovy (obesity). Tirzepatide is called Mounjaro in the EU (approved for both) and additionally Zepbound in the US (the brand name for weight loss there). ^[8]

The approval is the decisive everyday difference: Wegovy and Mounjaro are approved in the EU for weight management. Ozempic is approved only for type 2 diabetes, any use for weight loss is off-label. Off-label does not automatically mean dangerous, but it worsens supply shortages for diabetics who need the drug medically. That is why Ozempic should not be promoted as a cheap weight-loss alternative. ^{[4, 8, 1]}

Both drugs are dosed up slowly (titration) so the gastrointestinal tract can adapt. Wegovy starts over 16 weeks in steps: weeks 1 to 4 at 0.25 mg, weeks 5 to 8 at 0.5 mg, weeks 9 to 12 at 1.0 mg, weeks 13 to 16 at 1.7 mg, and from week 17 the standard maintenance dose 2.4 mg once a week injected under the skin. ^{[10, 11]} Since February 2026 a higher 7.2 mg dose is also approved in the EU, but the individual pen and its price are not yet established, so don't count on it yet.

Mounjaro starts at 2.5 mg and steps up every four weeks (2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg). Available maintenance doses are 5, 10 and 15 mg, the maximum dose is 15 mg once a week under the skin. ^{[12, 13]}

In the approval trial, people on tirzepatide lost on average roughly 15 to 21 percent of their body weight, more than on semaglutide and far more than on placebo. These are not marketing figures but results from large randomized trials (RCTs, the gold standard, where the draw decides who gets the drug or the dummy).

The central trial is SURMOUNT-1 (NEJM 2022, Jastreboff et al.), a phase 3 study in adults with obesity or overweight without diabetes over 72 weeks. Mean weight loss was minus 15.0 percent on 5 mg tirzepatide, minus 19.5 percent on 10 mg and minus 20.9 percent on 15 mg, versus minus 3.1 percent on placebo. ^{[14, 15]} Included were people with a BMI of 30 or higher, or BMI 27 or higher with at least one weight-related complication. ^[14]

A note on the numbers so you don't get confused if you read higher ones elsewhere: the figures here are the conservative treatment-regimen estimand, the analysis that counts all participants regardless of whether they stayed on therapy. Manufacturers and the press often quote the more optimistic figure (up to about 22.5 percent), which looks only at the strictly adherent. Both sets of numbers are real, they just measure different things. They should not be mixed.

The share of strong responders was high too. In SURMOUNT-1, at least 20 percent of body weight was lost by 30.0 percent (5 mg), 50.1 percent (10 mg) and 56.7 percent (15 mg) of those treated. ^[15] So more than every second person on the top dose reached a fifth less weight.

For comparison with semaglutide: in STEP-1 (NEJM 2021, Wilding et al.) semaglutide 2.4 mg led to minus 14.9 percent after 68 weeks versus minus 2.4 percent on placebo, and 86 percent reached at least 5 percent weight loss. ^[16]

The head-to-head comes from SURMOUNT-5 (NEJM 2025, Aronne et al.): tirzepatide versus semaglutide directly, 72 weeks, 751 participants without diabetes. Tirzepatide reached minus 20.2 percent, semaglutide minus 13.7 percent, an advantage of about 6.5 percentage points for tirzepatide. ^[9]

On blood sugar, too, tirzepatide leads. In SURPASS-2 (NEJM 2021, Frias et al.) in type 2 diabetes, tirzepatide 15 mg lowered HbA1c (the long-term blood sugar value of the past weeks) over 40 weeks by 2.30 percentage points, semaglutide 1 mg by 1.86 percentage points. ^[17]

Important for the full picture: these percentages apply to the trial period under medical supervision and as an addition to diet and exercise. They say nothing about what happens after stopping. That is exactly what we look at below.

By far the most common side effects are gastrointestinal complaints, usually mild to moderate and mostly during titration. Alongside that there are a few rarer but more serious risks and a few myths that cause more fear than the data warrant. Here is the honest overview.

Gastrointestinal. In SURMOUNT-1, on tirzepatide (5 / 10 / 15 mg) 24.6 / 33.3 / 31.0 percent reported nausea, 18.7 / 21.2 / 23.0 percent diarrhea, 16.8 / 17.1 / 11.7 percent constipation and 8.3 / 10.7 / 12.2 percent vomiting, versus 9.5 percent nausea and 7.3 percent diarrhea on placebo. ^[15] Therapy was stopped due to side effects by 4.3 / 7.1 / 6.2 percent versus 2.6 percent on placebo. ^[15] Most complaints ease over time.

Gallbladder. Here the risk is genuinely raised. A meta-analysis of 76 RCTs with 103,371 patients (He et al., JAMA Intern Med 2022) found a relative risk (RR) of 1.27 for gallstones, 1.36 for gallbladder inflammation and 1.55 for biliary disease. In the weight-loss trials with higher doses the RR was even 2.29, so a good two times higher than without treatment. ^[18] Rapid weight loss favors gallstones anyway, and the drug amplifies that effect.

Pancreas (pancreatitis). Contrary to earlier worry, pooled placebo-controlled RCTs show no consistent raised class risk. A meta-analysis (Wen et al. 2025) found no significant increase (a pooled odds ratio, the odds compared with placebo, of about 0.99, and a value near 1.0 means no difference, for semaglutide even about 0.7). ^[19] The warning stays in the package insert as a precaution, and people with a history of pancreatitis are excluded as a precaution. But this should not be presented as a proven risk.

Thyroid. There is a lot of fear-mongering here, so to be clear: semaglutide and tirzepatide triggered dose- and time-dependent thyroid C-cell tumors in rodent studies. That is why the drugs are contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or with MEN-2 syndrome. But whether this transfers to humans is unclear: the GLP-1 receptor is barely expressed in normal human thyroid C-cells, and trials and post-marketing data have so far shown no rise in MTC in humans. The contraindication is a precaution, not proof that the jab causes thyroid cancer. ^[20]

Muscle loss. A substantial part of the weight lost is not fat but lean mass. That is important enough for its own section, see keeping muscle on GLP-1 below. ^[21]

Ozempic face. Sunken cheeks and temples, looser skin: this is a consequence of rapid weight loss, namely the shrinking of the facial fat pads while skin elasticity lags behind. It is not a direct drug effect, it happens with any fast weight loss. This explanation comes from dermatology explainers, not controlled trials, but it is considered plausible. ^[22]

The weight-loss jab is a medical obesity therapy, not a beauty tool for the last few kilos. The approval draws the line clearly, and it explicitly requires a lifestyle program alongside it.

The EMA indication (European Medicines Agency) for Wegovy and Mounjaro reads: as an addition to a calorie-reduced diet and more exercise for weight management in adults with a BMI of 30 or higher (obesity), or BMI 27 to under 30 (overweight) plus at least one weight-related comorbidity such as high blood pressure, a lipid disorder, sleep apnea, cardiovascular disease or prediabetes. ^{[10, 12]}

For minor, cosmetic weight loss, by contrast, the jab is not intended. Anyone with a normal BMI who wants to drop a few kilos does not fall under the indication, and the benefit-risk balance then shifts unfavorably. ^{[10, 12]}

Decisive, and often left out of the marketing: the jab does not replace lifestyle. The approval explicitly requires it as an addition to reduced calorie intake and more exercise. ^{[10, 12]} Anyone who doesn't touch their diet at all gives away part of the effect and part of muscle preservation. A much gentler, weaker-evidence lever on satiety is fiber, covered in detail in the guide on fiber and fibermaxxing. And anyone looking for a plant-based alternative without a prescription should know that berberine as a natural Ozempic is discussed but is nowhere near the league of prescription GLP-1 drugs. Don't confuse the two.

The most important point for any cost-benefit calculation comes last, and it is uncomfortable: the weight regain after stopping. In the STEP-1 extension (Wilding et al., Diabetes Obes Metab 2022), after stopping semaglutide plus lifestyle, participants regained about two thirds of the weight they had lost (plus 11.6 percentage points over 52 weeks). One year after the end of therapy the net weight loss was only minus 5.6 percent compared with the study start, instead of the minus 17.3 percent during therapy. ^[23]

The honest consequence is a long-term therapy: stopping typically leads to regain. That belongs in any honest indication and cost calculation, because it turns the picture from a one-off monthly price into a long-term commitment. ^[23]

A large part of the weight loss on GLP-1 is not fat but lean mass, meaning muscle and other fat-free tissue. In recent studies this lean-mass loss made up 26 to 40 percent of total weight loss. ^[21] That sounds alarming at first, but it is only half as bad once you put it in context and counteract it.

The range depends on the drug and the measurement. In the DXA subset of STEP-1 (semaglutide) about 40 percent of the loss was lean mass, in the DXA subset of SURMOUNT-1 (tirzepatide) about 26 percent. ^{[21, 24]} DXA is a body scan that measures fat and lean mass separately. These individual figures are secondarily derived, so read them as a rough range of about a quarter to 40 percent, not as exact values.

Now the context that takes the wind out of the panic: lean-mass loss is largely normal with rapid weight loss, even on a diet with no drug at all you lose some muscle along with it. ^[21] So the right question is not whether but how you minimize it.

The most effective non-drug strategy, with the best evidence, is clear: strength training (progressive resistance, meaning gradually more load) plus enough protein. In a case series the subjects trained with weights three to five times a week and ate a lot of protein (1.6 to 2.3 g per kg of fat-free mass), and their lean mass was in part even maintained or rose slightly. ^[21] As a workable rule of thumb, at least 1.2 g of protein per kg of body weight a day applies, rather more.

How exactly you should time protein and training, what protein amounts are realistic and what to watch for in blood work is covered in detail in the dedicated guide on keeping muscle on GLP-1. The short version here: anyone who loses weight without strength training and without minding protein gives away part of their muscle, and that muscle is exactly what you need long term for metabolism and independence in old age.

The next generation is on the horizon, and in the trials so far it works even more strongly. The most important drug is called retatrutide (trial code LY3437943), a triple agonist: it acts on the GIP, GLP-1 and glucagon receptors at the same time, so three levers instead of one or two. ^[25]

In the phase 2 trial (NEJM 2023, Jastreboff et al.) over 48 weeks, mean weight loss at the highest dose (12 mg) was minus 24.2 percent versus minus 2.1 percent on placebo, and at 8 mg it was minus 22.8 percent. ^[25] These are the highest figures reported so far for a weight-loss drug, though from an early trial phase. The side-effect profile is class-typical, mainly nausea, vomiting and diarrhea. ^[25]

The decisive point to close on, so no false expectation arises: retatrutide is not yet approved in the EU and remains in trials. You cannot get it prescribed in Germany, and anything that shows up online as a source belongs to the grey market that this guide deliberately does not cover. See the triple agonists as an exciting outlook, not an option for 2026.